Brief: Rani Therapeutics Announces Preclinical Pharmacodynamic Data On Transenteric Delivery Of GLP-1 Incretin Triagonist

Rani Therapeutics Holdings

14/12/2023 13:17

Dec 14 (Reuters) - Rani Therapeutics Holdings Inc
 RANI.O :
    * RANI THERAPEUTICS ANNOUNCES PRECLINICAL PHARMACODYNAMIC
DATA ON
TRANSENTERIC DELIVERY OF GLP-1 INCRETIN TRIAGONIST
    * RANI THERAPEUTICS HOLDINGS INC - PRECLINICAL DATA SUPPORT
POTENTIAL FOR RANIPILL PLATFORM TO ENABLE ORAL DELIVERY OF
MULTIPLE OBESITY TREATMENTS
    * RANI - BELIEVE DATA ARE REFLECTIVE OF POTENTIAL
CONTRIBUTIONS
RANIPILL CAPSULE CAN MAKE TO GLP-1 RECEPTOR AGONIST SPACE,
BROADER OBESITY MARKET
    * RANI THERAPEUTICS HOLDINGS INC - EVALUATING OPTIONS WITH
INTENTION TO MOVE FORWARD WITH ONE OR MORE PRODUCTS IN GLP-1
RECEPTOR AGONIST SPACE
    * RANI THERAPEUTICS HOLDINGS INC - DEVELOPMENT OF RANIPILL
HC TO
BE READY FOR POTENTIAL PHASE 1 CLINICAL TRIALS IN SECOND HALF OF
2024
    * RANI THERAPEUTICS - TOPLINE RESULTS OF PHASE 1 CLINICAL
TRIAL OF
RT-111, A RANIPILL GO CONTAINING USTEKINUMAB BIOSIMILAR CT-P43,
EXPECTED IN Q1 2024
    * RANI THERAPEUTICS HOLDINGS - INITIATION OF PHASE 2
CLINICAL
TRIAL OF RT-102, A RANIPILL GO CONTAINING TERIPARATIDE FOR
OSTEOPOROSIS, EXPECTED IN 2024

Source text for Eikon:  ID:nGNX5xqQmR 
Further company coverage:  RANI.O 

 ((Reuters.Briefs@thomsonreuters.com;))